Log in to search using one of your social media accounts:

 

Caster Semenya could be forced to undertake hormone therapy for future Olympics

Study shows performance-boosting effects of testosterone in female athletes, reopening controversial debate about intersex and hyperandrogenous competitorsUsing testosterone to categorise male and female athletes isn ’t perfect, but it’s the best solution we haveCaster Semenya, the Olympic 800m champion, may be banned from competing at future Games unless she undergoes hormone replacement therapy (HRT) or even surgery in the wake of a landmark study into athletes with raised testosterone levels which has just been published.The International Association of Athletics Federations, the world governing body, commissioned research which has produced the most conclusive evidence yet that female athletes with very high levels of naturally occurring testosterone receive significant performance-enhancing benefits in competition.Continue reading...
Source: Guardian Unlimited Science - Category: Science Authors: Tags: Athletics Caster Semenya IAAF Sport Science World news Olympic Games Sport politics Gender Source Type: news

Related Links:

Conclusions:The available literature suggests that HT is a viable option for the primary prevention of cardiovascular disease in postmenopausal women. Newer trials will likely verify this assessment. If this is enough to change clinical practice, however, remains to be seen given the general fear of HT by many with prescriptive authority, and also the women in our care. Objective: Clinical trials in menopause have undergone much scrutiny over the years. This has led to significant shifts in the treatment of symptomatic menopause and a substantial impact on women. We aim to delineate the key studies contributing to this...
Source: Menopause - Category: OBGYN Tags: Clinical Corner: Invited Review Source Type: research
This article is protected by copyright. All rights reserved.
Source: International Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Research Article Source Type: research
Publication date: February 2018 Source:Journal of Functional Foods, Volume 41 Author(s): Naice E.S. Monteiro, Lívia D. Queirós, Danielle B. Lopes, Adriana O. Pedro, Gabriela A. Macedo Menopause is a natural event that occurs in women around the age of 50 years, causing irregularities in the menstrual cycle until its complete end, due to the hormonal deficit, especially estrogen, that causes several unpleasant urogenital and vasomotor symptoms. Hormone replacement therapy has many benefits, but should be prescribed with caution in women with a history of stroke, thromboembolic events, certain types of cance...
Source: Journal of Functional Foods - Category: Nutrition Source Type: research
ConclusionsMore than 50% in the total cohort had hormone replacement. Although adherence was generally good, this study shows that hormone replacement therapy may be improved. This may be achieved by better individualization of the treatment and by providing specific information to patients regarding both long‐term and short‐term hormonal effects and side effects.
Source: Clinical Endocrinology - Category: Endocrinology Authors: Tags: ORIGINAL ARTICLE Source Type: research
Abstract Background/AimTo evaluate and stratify early cardiovascular risk of transsexuals who underwent pharmacological and/or surgical gender reassignment. MethodsFifty‐six transsexuals were divided into two groups: group 1 – underwent gonadectomy (orchiectomy for transwomen and hystero‐annessiectomy for transmen); group 2 – hormone replacement therapy alone. All participants underwent carotid artery intima‐media thickness (C‐IMT) and flow‐mediated vasodilation (FMD) of brachial artery evaluations. ResultsFMD was lower in patients who had undergone gonadectomy compared with non‐surgically treated p...
Source: Internal Medicine Journal - Category: Internal Medicine Authors: Tags: Original Article Source Type: research
ConclusionsMore than 50% in the total cohort had hormone replacement. Although adherence was generally good, this study shows that hormone replacement therapy may be improved. This may be achieved by better individualization of the treatment and by providing specific information to patients regarding both long term and short‐term hormonal effects and side effects.This article is protected by copyright. All rights reserved.
Source: Clinical Endocrinology - Category: Endocrinology Authors: Tags: Original Article Source Type: research
Authors: Gambacciani M, Biglia N, Cagnacci A, DI Carlo C, Caruso S, Cicinelli E, DE Leo V, Farris M, Gambera A, Guaschino S, Lanzone A, Paoletti AM, Russo N, Vicariotto F, Villa P, Volpe A Abstract In the last decade the risk benefits ratio of HRT has been reevaluated mainly in tens of cardiovascular risk. Present Consensus Statement is largely inspired by the Global Consensus on Menopausel Hormone Therapy in 2013 and 2016 by leading global menopause societies (The American Society for Reproductive Medicine, The Asia Pacific Menopause Federation, The Endocrine Society, The European Menopause and Andropause Society,...
Source: Minerva Ginecologica - Category: OBGYN Tags: Minerva Ginecol Source Type: research
CONCLUSION: Until additional studies are performed, the risks and benefits must be weighed on an individual basis with consideration of prophylaxis when a decision is made to continue these medications in the perioperative period. Part of this decision making includes the risk of fetal harm in an unwanted pregnancy in preparation for nonobstetric surgery versus an increased risk of venous thromboembolism. PMID: 28969534 [PubMed - as supplied by publisher]
Source: Current Clinical Pharmacology - Category: Drugs & Pharmacology Authors: Tags: Curr Clin Pharmacol Source Type: research
It’s not going to kill you to take hormone replacement therapy. That’s the take home message from the latest analysis of the Women’s Health Initiative, the largest and longest randomized trial of hormone replacement therapy (HRT) in menopausal women. After almost 18 years of follow up in the WHI, there was no increase in overall mortality, including death rates from cancer, in women taking HRT for up to 5.6 years (estrogen plus progestin) or 7.2 years (estrogen alone). There was a non-significant reduction in mortality among those who started HRT between ages 50 and 59, the group most likely to ...
Source: The Blog That Ate Manhattan - Category: Primary Care Authors: Tags: Hormone Replacement Menopause WHI breast cancer estrogen HRT Prempro Source Type: blogs
CONCLUSIONS: A small single trial contributed evidence of moderate quality that the use of growth hormone for a year may improve height velocity of children with thalassaemia although height SD score in the treatment group was similar to the control group. There are no randomised controlled trials in adults or trials that address the use of growth hormone therapy over a longer period and assess its effect on final height and quality of life. The optimal dosage of growth hormone and the ideal time to start this therapy remain uncertain. Large well-designed randomised controlled trials over a longer period with sufficient du...
Source: Cochrane Database of Systematic Reviews - Category: General Medicine Authors: Tags: Cochrane Database Syst Rev Source Type: research
More News: Hormonal Therapy | Hormone Replacement Therapy | Hormones | Politics | Science | Sports Medicine | Study